Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
graft-versus-host disease
Biotech
Orca prepares to make market plunge after phase 3 win
Orca-T offers “good efficacy and low toxicity,” CEO Ivan Dimov said, noting that the combination of features represents the "holy grail" in the space.
Gabrielle Masson
Mar 17, 2025 7:00am
MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing
Jan 9, 2025 5:18am
Viral protein suppresses graft vs. host disease in mice
Jul 19, 2024 5:30am
MaaT posts 18-month data showing 'clear OS advantage' in aGvHD
Apr 15, 2024 7:05am
Ironwood spies new frontier for $1B drug in exploratory trial
Mar 28, 2024 9:00am
BioSenic plots path past biotech graveyard and into phase 3
Oct 25, 2023 10:31am
